Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

Next Previous
Trial Profile

RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zoldonrasib (Primary) ; Fluorouracil+Folinic acid+Irinotecan+Oxaliplatin; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic ductal carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms RASolute 305
  • Sponsors REVOLUTION Medicines

Most Recent Events

  • 24 Jun 2026 According to a Revolution Medicines media release, data from this study will be presented at the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress, taking place July 1-4, 2026 in Munich, Germany.
  • 23 Jun 2026 According to Revolution Medicines media release, company announced that it has begun treating patients in this trial.
  • 09 Mar 2026 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top